Akari Therapeutics (AKTX) Proxy filing summary

Executive summary

• The annual general meeting is scheduled for June 30, 2026, with voting on 18 resolutions covering financial, governance, compensation, and capital matters.

• Shareholders and ADS holders are provided detailed instructions for voting, with a quorum set at 33 1/3% of share capital.

• The board unanimously recommends voting in favor of all proposed resolutions, emphasizing alignment with shareholder interests.

Voting matters and shareholder proposals

• Resolutions include approval of statutory accounts, remuneration report and policy, re-election of six directors, auditor appointments, and several capital-related authorizations.

• Shareholder approval is sought for issuances under the ELOC Purchase Agreement, new warrants, a potential change of control, and general share allotment and pre-emption rights disapplication.

• Advisory votes on executive compensation and director remuneration are included, with results considered for future policy but non-binding.

Board of directors and corporate governance

• The board is divided into three classes, with six Class A directors up for re-election for one-year terms.

• All board committees (audit, compensation, nominating/governance) are composed of independent directors, except for executive roles.

• The board separates the roles of Chairman and CEO to reinforce independent oversight.

• Shareholders can recommend or nominate directors and communicate directly with the board.